Institution
Lou Ruvo Brain Institute
Facility•Las Vegas, Nevada, United States•
About: Lou Ruvo Brain Institute is a facility organization based out in Las Vegas, Nevada, United States. It is known for research contribution in the topics: Dementia & Population. The organization has 169 authors who have published 566 publications receiving 20240 citations.
Topics: Dementia, Population, Cognitive decline, Cognition, Clinical trial
Papers published on a yearly basis
Papers
More filters
••
French Institute of Health and Medical Research1, Pierre-and-Marie-Curie University2, University of British Columbia3, UBC Hospital4, Beta5, Sahlgrenska University Hospital6, University of Virginia7, McGill University8, Brigham and Women's Hospital9, Washington University in St. Louis10, Vita-Salute San Raffaele University11, University College London12, University of Antwerp13, University of Geneva14, University of California, San Diego15, University of Kentucky16, Karolinska University Hospital17, university of lille18, University of California, San Francisco19, University of Nice Sophia Antipolis20, Brown University21, University of Paris22, Universidade Federal de Minas Gerais23, Maastricht University Medical Centre24, University of Southern California25, NewYork–Presbyterian Hospital26, VU University Amsterdam27, Lou Ruvo Brain Institute28
TL;DR: It is proposed that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease.
Abstract: In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging-Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's disease (AD) that better define clinical phenotypes and integrate biomarkers into the diagnostic process, covering the full staging of the disease. This Position Paper considers the strengths and limitations of the IWG research diagnostic criteria and proposes advances to improve the diagnostic framework. On the basis of these refinements, the diagnosis of AD can be simplified, requiring the presence of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker consistent with the presence of Alzheimer's pathology. We propose that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. This paper also elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, and for the preclinical states of AD.
2,581 citations
••
TL;DR: It is demonstrated that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem, and the success rate for advancing from one phase to another is low and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area.
Abstract: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
1,399 citations
••
Verneri Anttila1, Verneri Anttila2, Brendan Bulik-Sullivan1, Brendan Bulik-Sullivan2 +717 more•Institutions (270)
TL;DR: It is demonstrated that, in the general population, the personality trait neuroticism is significantly correlated with almost every psychiatric disorder and migraine, and it is shown that both psychiatric and neurological disorders have robust correlations with cognitive and personality measures.
Abstract: Disorders of the brain can exhibit considerable epidemiological comorbidity and often share symptoms, provoking debate about their etiologic overlap. We quantified the genetic sharing of 25 brain disorders from genome-wide association studies of 265,218 patients and 784,643 control participants and assessed their relationship to 17 phenotypes from 1,191,588 individuals. Psychiatric disorders share common variant risk, whereas neurological disorders appear more distinct from one another and from the psychiatric disorders. We also identified significant sharing between disorders and a number of brain phenotypes, including cognitive measures. Further, we conducted simulations to explore how statistical power, diagnostic misclassification, and phenotypic heterogeneity affect genetic correlations. These results highlight the importance of common genetic variation as a risk factor for brain disorders and the value of heritability-based methods in understanding their etiology.
1,357 citations
••
Pierre-and-Marie-Curie University1, AXA2, University of British Columbia3, VU University Medical Center4, University of Southern California5, University of Toulouse6, ICM Partners7, French Institute of Health and Medical Research8, University of Lübeck9, Imperial College London10, Sahlgrenska University Hospital11, Federal Institute for Drugs and Medical Devices12, UCL Institute of Neurology13, University of Bordeaux14, University of Geneva15, McGill University16, University of Paris17, University of Washington18, Karolinska University Hospital19, University of Eastern Finland20, University of North Texas Health Science Center21, University of California, San Francisco22, University of Melbourne23, Brown University24, Brigham and Women's Hospital25, Harvard University26, Alzheimer's Association27, Lou Ruvo Brain Institute28, Mayo Clinic29
TL;DR: An updated review of the literature and evidence on the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage of Alzheimer's disease are provided.
Abstract: During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
1,235 citations
••
TL;DR: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD.
603 citations
Authors
Showing all 172 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jeffrey L. Cummings | 148 | 833 | 116067 |
Richard M. Ransohoff | 127 | 490 | 67439 |
James B. Leverenz | 80 | 274 | 24935 |
Stephen M. Rao | 78 | 237 | 26994 |
Marwan N. Sabbagh | 73 | 353 | 23713 |
Rema Raman | 59 | 199 | 13921 |
Christopher H. van Dyck | 55 | 163 | 14044 |
Michael C. Donohue | 48 | 160 | 11382 |
Bruce T. Lamb | 45 | 126 | 9320 |
Susan M. Staugaitis | 38 | 70 | 8196 |
Zaven S. Khachaturian | 34 | 93 | 6503 |
Lara Jehi | 33 | 166 | 3748 |
Zoltan Mari | 30 | 118 | 5894 |
Charles Bernick | 28 | 64 | 4100 |
Dietmar Cordes | 25 | 81 | 4606 |